Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Yong Sang Hong, Jeeyun Lee, Hye Sook Han, Soo Jung Lee, Jin-Soo Kim, Baek-Yeol Ryoo | ||||||||||||
Title | First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors. | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570 | ||||||||||||
Abstract Text | Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2570-2570 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS mutant | melanoma | predicted - sensitive | Belvarafenib | Case Reports/Case Series | Actionable | In a Phase I trial, Belvarafenib (HM95573) treatment resulted in an unconfirmed partial response in a patient with NRAS mutant melanoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2570-2570; NCT02405065). | detail... |